Cibelly Goulart

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8608340/publications.pdf

Version: 2024-02-01

15	429	840728 11	996954 15
papers	citations	h-index	g-index

16	16	16	521
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Control of human toxoplasmosis. International Journal for Parasitology, 2021, 51, 95-121.	3.1	91
2	Substrate-mediated regulation of the arginine transporter of Toxoplasma gondii. PLoS Pathogens, 2021, 17, e1009816.	4.7	9
3	Early pneumococcal clearance in mice induced by systemic immunization with recombinant BCG PspA-PdT prime and protein boost correlates with cellular and humoral immune response in bronchoalveolar fluids (BALF). Vaccine: X, 2020, 4, 100049.	2.1	5
4	A Bivalent RecombinantMycobacterium bovisBCG Expressing the S1 Subunit of the Pertussis Toxin Induces a Polyfunctional CD4⁺T Cell Immune Response. BioMed Research International, 2019, 2019, 1-7.	1.9	8
5	Rational selection of broadly cross-reactive family 2 PspA molecules for inclusion in chimeric pneumococcal vaccines. Microbial Pathogenesis, 2017, 109, 233-238.	2.9	12
6	Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy. Vaccine, 2017, 35, 1683-1691.	3.8	14
7	A Combination of Recombinant Mycobacterium bovis BCG Strains Expressing Pneumococcal Proteins Induces Cellular and Humoral Immune Responses and Protects against Pneumococcal Colonization and Sepsis. Vaccine Journal, 2017, 24, .	3.1	11
8	New Recombinant Mycobacterium bovis BCG Expression Vectors: Improving Genetic Control over Mycobacterial Promoters. Applied and Environmental Microbiology, 2016, 82, 2240-2246.	3.1	24
9	Current status and perspectives on protein-based pneumococcal vaccines. Critical Reviews in Microbiology, 2015, 41, 190-200.	6.1	79
10	Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes. Vaccine, 2014, 32, 4104-4110.	3.8	31
11	Conjugation of Polysaccharide 6B from Streptococcus pneumoniae with Pneumococcal Surface Protein A: PspA Conformation and Its Effect on the Immune Response. Vaccine Journal, 2013, 20, 858-866.	3.1	26
12	Characterization of Protective Immune Responses Induced by Pneumococcal Surface Protein A in Fusion with Pneumolysin Derivatives. PLoS ONE, 2013, 8, e59605.	2.5	42
13	Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine, 2011, 29, 1634-1642.	3.8	47
14	Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14â€"Lysine modified PspA. Vaccine, 2011, 29, 8689-8695.	3.8	15
15	Production and purification of recombinant fragment of pneumococcal surface protein A (PspA) in Escherichia coli. Procedia in Vaccinology, 2011, 4, 27-35.	0.4	11